research Implementing patient safety and quality improvement in dermatology. Part 1: Patient safety science
The document concludes that improving patient safety and quality is increasingly important in dermatology.
Search
for
Sort by
Research
30 / 1000+ results 
research Patient-reported treatment outcomes and safety of direct-to-consumer teledermatology for finasteride treatment in male androgenetic alopecia: A cross-sectional study
Most men using teledermatology for hair loss treatment saw improved hair and self-esteem, with some experiencing side effects.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research JAAD Game Changers: Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Low-dose oral minoxidil is safe for treating hair loss, especially in women, with side effects stopping after use ends.
research Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Low-dose oral minoxidil safely treats hair loss, with hypertrichosis as main side effect.
research Efficacy and safety of baricitinib in patients with refractory alopecia areata
Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
research Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study
Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen
Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
research Safety measures in high-risk patients with cardiovascular disease and elderly patients undergoing hair restoration surgery
Extra safety steps are needed for older patients and those with heart disease having hair restoration surgery.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Robotsebészet a betegbiztonság szolgálatában = Robotic surgery in the service of patient safety
Robotic surgery improves patient safety and surgical quality.
research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients
Oral bicalutamide is safe and effective for female hair loss.
research Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
research Safety Considerations and Monitoring in Patients Treated with Systemic Medications for Acne
Some acne medications have side effects; doctors should educate patients and may not need to do frequent lab tests for all.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
Tracnil™, a mix of myo-inositol, folic acid, and vitamin D3, safely reduced acne, improved excessive hair growth, and fixed irregular periods in overweight women with PCOS.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
research Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.